Agile Therapeutics has launched its IPO after pricing its over 9.16 million shares at $6 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “AGRX.” RBC Capital Markets and William Blair & Company are the lead underwriters. Based in Princeton, NJ, Agile Therapeutics develops prescription contraceptives. Its backers include Aisling Capital, Care Capital, Investor Growth Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital.
PRINCETON, N.J., May 22, 2014 /PRNewswire/ — Agile Therapeutics, Inc., a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the pricing of its initial public offering of 9,166,667 shares of its common stock at a public offering price of $6.00 per share. Agile Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 1,375,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Global Market, beginning on May 23, 2014, under the symbol “AGRX.” The offering is expected to close on May 29, 2014, subject to customary closing conditions.
The joint book-running managers for the offering are RBC Capital Markets, LLC and William Blair & Company, L.L.C. In addition, Cantor Fitzgerald & Co. and Janney Montgomery Scott LLC are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 22, 2014. The offering is being made by means of a prospectus, copies of which may be obtained from RBC Capital Markets, LLC, Attention: Equity Syndicate, Three World Financial Center, 200 Vesey Street, 8th Floor, New York, NY 10281 Telephone (877) 822-4089 and William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, Telephone: (800) 621-0687 or by email at firstname.lastname@example.org.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.